Lyell Immunopharma (LYEL) said Wednesday it has started a phase 3 head-to-head trial of LYL314 in patients with relapsed or refractory large B-cell lymphoma.

The study will evaluate LYL314 compared to liso-cel and axi-cel therapies in the second-line setting, the company said.

Lyell said LYL314 is a dual-targeting CD19/CD20 CAR T-cell therapy that has received Regenerative Medicine Advanced Therapy and Fast Track designations from the US Food and Drug Administration.